JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger

JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.